# A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma

Source: https://onco.cc/trials/nct07189065/  
OnCo record `nct07189065` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Rocbrutinib, Bendamustine, Rituximab in diffuse large b-cell lymphoma, run by Guangzhou Lupeng Pharmaceutical Company LTD., now recruiting.

## Summary

A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma is a phase 2 interventional study registered as NCT07189065 by Guangzhou Lupeng Pharmaceutical Company LTD., with 150 participants planned, started 2025-11-27 and due to reach its primary completion in 2027-12-31. Interventions recorded: Rocbrutinib, Bendamustine, Rituximab, Lenalidomide. Conditions listed: Diffuse Large B-Cell Lymphoma (DLBCL). No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07189065
- Phase: 2
- Setting: An Open-Label, Randomized Controlled, Multicenter, Phase II Clinical Study to Evaluate the Efficacy and Safety of Rocbrutinib Monotherapy Versus Investigator's Choice of Therapy in Patients With Relapsed or Refractory Non-GCB Diffuse Large B-Cell Lymphoma
- Sponsor: Guangzhou Lupeng Pharmaceutical Company LTD.
- Enrolled: 150

## Sources

- ClinicalTrials.gov NCT07189065: https://clinicaltrials.gov/study/NCT07189065

## Connected records

- cancers: [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/)
- drugs: [Bendamustine](https://onco.cc/drugs/bendamustine/), [Lenalidomide](https://onco.cc/drugs/lenalidomide/), [Rituximab](https://onco.cc/drugs/rituximab/), [Rocbrutinib](https://onco.cc/drugs/rocbrutinib/)

---
JSON: https://onco.cc/api/v1/entities/nct07189065.json